<DOC>
	<DOCNO>NCT00558519</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop growth cancer cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill cancer cell . PURPOSE : This phase II trial study well combination chemotherapy work treat young patient newly diagnose acute lymphoblastic leukemia .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>OUTLINE : This multicenter study . The purpose study improve outcome adolescent young adult acute lymphoblastic leukemia ( ALL ) . The objective study describe . OBJECTIVES : - To describe outcome ( i.e. , complete response rate , event-free survival , disease-free survival [ DFS ] , overall survival [ OS ] ) adolescents young adult newly diagnose acute lymphoblastic leukemia ( ALL ) treat pediatric chemotherapy regimen adult hematologists/oncologists multiple site . - To explore feasibility extend `` pediatric approach '' adult patient 40 year age . - To estimate DFS OS patient . - To describe toxicity observe patient . - To compare outcomes patient treat protocol appropriate similar patient ( age disease characteristic ) treat pediatric oncologist protocol COG-AALL0232 . - To evaluate adherence adult hematologists/oncologists patient `` pediatric '' ALL treatment regimen identify reason variance . - To analyze describe outcome patient treat study accord pretreatment characteristic age , gender , white blood cell count , hematologic parameter , blood chemistry , immunophenotype , cytogenetics molecular genetic characteristic , treatment variable treatment site ( academic center community ) , protocol adherence . - To analyze describe outcome patient treat study accord baseline psychosocial characteristic , demographic , family support . The course treatment research study describe . - Remission induction therapy : Patients receive intrathecal ( IT ) cytarabine day 1 ; vincristine IV day 1 , 8 , 15 , 22 ; prednisone IV orally twice daily day 1-28 ; daunorubicin hydrochloride IV day 1 , 8 , 15 , 22 ; pegaspargase IV intramuscularly ( IM ) day 4 5 6 ; IT methotrexate day 8 29* . Patients undergo bone marrow aspirate ( BMA ) biopsy day 29 ass induction response minimal residual disease status . Patients M1 marrow ( &lt; 1 % lymphoblast ) proceed remission consolidation therapy . Patients M2 marrow ( &gt; 5 % &lt; 25 % lymphoblast ) proceed extend remission induction therapy . Patients M3 marrow remove protocol therapy . NOTE : *Patients CNS3 disease also receive IT methotrexate day 15 22 . - Extended remission induction therapy : Patients receive prednisone IV orally twice daily day 1-14 ; vincristine IV day 1 8 ; pegaspargase IM IV day 4 5 6 ; daunorubicin hydrochloride IV day 1 . Patients undergo BMA biopsy day 15 . Patients M1 marrow proceed remission consolidation therapy . Patients M2 M3 bone marrow remove protocol therapy . - Remission consolidation therapy : Patients receive cyclophosphamide IV day 1 29 ; cytarabine IV subcutaneously ( SC ) day 1-4 , 8-11 , 29-32 , 36-39 ; oral mercaptopurine day 1-14 29-42 ; vincristine IV day 15 , 22 , 43 , 50 ; pegaspargase IM IV day 15 43 ; IT methotrexate day 1 , 8 , 15* , 22* . Once blood count recover , patient proceed interim maintenance therapy . NOTE : *Patients CNS3 disease receive IT methotrexate day 15 22 . - Interim maintenance therapy : Patients receive vincristine IV methotrexate ( Capizzi methotrexate ) IV day 1 , 11 , 21 , 31 , 41 ; pegaspargase IM IV day 2 22 ; IT methotrexate day 1 31 . Once blood count recover ( ANC ≥ 750/mm^3 platelet count ≥ 75,000/mm^3 ) , patient proceed delay intensification therapy . - Delayed intensification therapy : Patients receive vincristine IV day 1 , 8 , 15 , 43 , 50 ; dexamethasone IV orally twice daily day 1-7 15-21 ; doxorubicin hydrochloride IV day 1 , 8 , 15 ; pegaspargase IM IV day 4 5 6 AND day 43 ; cyclophosphamide IV day 29 ; cytarabine IV SC day 29-32 36-39 ; oral thioguanine day 29-42 ; IT methotrexate day 1 , 29 , 36 . Once blood count recover , patient proceed maintenance therapy . - Maintenance therapy : Patients receive vincristine IV day 1 , 29 , 57 ; dexamethasone IV orally twice daily day 1-5 , 29-33 , 57-61 ; mercaptopurine orally day 1-84 ; IT methotrexate day 1* ; oral methotrexate day 8 , 15 , 22 , 29** , 36 , 43 , 50 , 57 , 64 , 71 , 78 . Treatment repeat every 12 week 2 year start interim maintenance ( female patient ) 3 year start interim maintenance ( male patient ) . NOTE : *IT methotrexate also give day 29 first 4 course maintenance therapy . NOTE : **Oral methotrexate hold day 29 first 4 course maintenance therapy ( IT methotrexate give ) . - Radiotherapy : During first course maintenance therapy , patient testicular disease undergo concurrent radiotherapy testes 5 day week 2.5 week ( total dose 2400 cGy give 12 daily fraction ) ; patient CNS3 disease undergo concurrent cranial radiotherapy 5 day week 2 week ( total dose 1800 cGy give 10 daily fraction ) ; patient T-cell ALL undergo concurrent cranial radiotherapy ( total dose 2400 cGy give 10 daily fraction ) 5 day week 2 week . Patients may complete survey end course 1 , 2 , 4 , end protocol treatment , 6 18 month end protocol treatment . After completion study treatment , patient follow every 1-3 month 3 year every 6 month 7 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Thioguanine</mesh_term>
	<criteria>Eligibility Criteria : 1 . Diagnosis 1 . Newly diagnose patient either Bprecursor Tprecursor acute lymphoblastic leukemia ( WHO criteria ) . Burkitt type leukemia define per protocol eligible . Patients know Ph+ ALL time diagnosis eligible . 2 . CALGB patient enter CALGB 10403 later find meet follow criterion Ph+ ALL treatment trial discontinue encouraged enroll CALGB 10001 successor trial : BCRABL fusion transcript determine FISH RTPCR ( 9 ; 22 ) ( q34 ; q11 ) variant determine cytogenetics NonCALGB study participant later find Ph+ treatment trial discontinue encouraged enroll appropriate clinical trial specifically design Ph+ ALL . 2 . Age : 16 39 year 3 . ECOG Performance Status 02 4 . Patients Down Syndrome exclude study due likelihood excessive toxicity result . These patient treat consultation pediatric oncologist . 5 . Prior Therapy No prior therapy except limited treatment corticosteroid hydroxyurea single dose intrathecal cytarabine . 1 . No prior therapy acute leukemia except emergency therapy ( corticosteroid hydroxyurea ) blast cell crisis , superior vena cava syndrome , renal failure due leukemic infiltration kidney . When indicated , leukapheresis exchange transfusion recommend reduce WBC . 2 . Singledose intrathecal cytarabine allow prior registration prior initiation systemic therapy patient convenience . This usually do time diagnostic bone marrow venous line placement avoid second lumbar puncture . Systemic chemotherapy must begin within 72 hour intrathecal therapy . 3 . Patients receive prior steroid therapy eligible study . The dose duration previous steroid therapy carefully document case report form .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>39 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>B-cell adult acute lymphoblastic leukemia</keyword>
	<keyword>T-cell adult acute lymphoblastic leukemia</keyword>
	<keyword>untreated adult acute lymphoblastic leukemia</keyword>
</DOC>